Equitable Holdings Inc. Makes New $585,000 Investment in Becton, Dickinson and Company $BDX

Equitable Holdings Inc. acquired a new position in Becton, Dickinson and Company (NYSE:BDX) in the 2nd quarter, HoldingsChannel.com reports. The institutional investor acquired 3,868 shares of the medical instruments supplier’s stock, valued at approximately $585,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in BDX. Imprint Wealth LLC bought a new stake in shares of Becton, Dickinson and Company during the 3rd quarter valued at about $25,000. SHP Wealth Management bought a new stake in Becton, Dickinson and Company in the fourth quarter worth approximately $26,000. Meeder Asset Management Inc. lifted its stake in Becton, Dickinson and Company by 152.2% in the first quarter. Meeder Asset Management Inc. now owns 169 shares of the medical instruments supplier’s stock valued at $27,000 after buying an additional 102 shares during the period. Main Street Group LTD bought a new position in shares of Becton, Dickinson and Company during the 1st quarter worth approximately $29,000. Finally, Bell Investment Advisors Inc bought a new position in shares of Becton, Dickinson and Company during the 2nd quarter worth approximately $29,000. 86.97% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other Becton, Dickinson and Company news, EVP Roland Goette sold 2,438 shares of Becton, Dickinson and Company stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $180.84, for a total transaction of $440,887.92. Following the transaction, the executive vice president directly owned 14,856 shares of the company’s stock, valued at $2,686,559.04. The trade was a 14.10% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Michael David Garrison sold 1,100 shares of the firm’s stock in a transaction dated Wednesday, June 24th. The shares were sold at an average price of $145.66, for a total transaction of $160,226.00. Following the transaction, the executive vice president directly owned 13,172 shares in the company, valued at $1,918,633.52. The trade was a 7.71% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 11,869 shares of company stock valued at $1,994,719 over the last quarter. 0.40% of the stock is owned by insiders.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on the stock. Citigroup reiterated a “buy” rating on shares of Becton, Dickinson and Company in a research note on Thursday, August 13th. Stifel Nicolaus set a $195.00 target price on shares of Becton, Dickinson and Company in a research note on Friday, August 7th. TD Cowen raised their price target on shares of Becton, Dickinson and Company from $163.00 to $182.00 and gave the stock a “hold” rating in a report on Wednesday, August 5th. Jefferies Financial Group reaffirmed a “buy” rating and issued a $210.00 price target on shares of Becton, Dickinson and Company in a research note on Thursday, August 6th. Finally, Weiss Ratings reiterated a “sell (d+)” rating on shares of Becton, Dickinson and Company in a report on Friday, August 7th. Eight analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Becton, Dickinson and Company presently has an average rating of “Hold” and an average target price of $185.67.

Becton, Dickinson and Company Stock Up 0.8%

Becton, Dickinson and Company stock opened at $189.71 on Friday. Becton, Dickinson and Company has a 1-year low of $127.59 and a 1-year high of $193.07. The firm has a market capitalization of $52.27 billion, a price-to-earnings ratio of 57.14, a price-to-earnings-growth ratio of 13.36 and a beta of 0.19. The firm’s fifty day moving average price is $166.14 and its two-hundred day moving average price is $160.53. The company has a current ratio of 0.87, a quick ratio of 0.51 and a debt-to-equity ratio of 0.55.

Becton, Dickinson and Company (NYSE:BDX) last posted its earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 EPS for the quarter, topping the consensus estimate of $3.14 by $0.09. The company had revenue of $4.98 billion during the quarter, compared to the consensus estimate of $4.89 billion. Becton, Dickinson and Company had a net margin of 4.52% and a return on equity of 14.79%. The firm’s revenue for the quarter was up 5.4% on a year-over-year basis. During the same period in the previous year, the firm posted $3.68 earnings per share. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. On average, equities research analysts predict that Becton, Dickinson and Company will post 12.67 earnings per share for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 30th. Shareholders of record on Wednesday, September 9th will be paid a dividend of $1.05 per share. The ex-dividend date is Wednesday, September 9th. This represents a $4.20 annualized dividend and a yield of 2.2%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is 126.51%.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.